Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Glenmark Pharmaceuticals Limited

http://www.glenmarkpharma.com

Latest From Glenmark Pharmaceuticals Limited

Five Big Pharma Products That Saw Action In India; There’s More To Come

Scrip spotlights the action around five key big pharma products in India. We track the gains made by Rybelsus and Keytruda, the wave of Januvia and Ibrance generics and on-market and court action for blockbuster Entresto.

Commercial India

Ibrance Generics Arrive In India, Patient Programs Add Free Drug Component

Pfizer’s Ibrance is set to lose exclusivity in the US only by 2027, but the Indian market is buzzing with activity as generics including from top-ranked drug maker Sun Pharma vie for a share of the pie. Competing CDK4/6 inhibitors are already available but can cut-price palbociclib versions alter market dynamics?

Generic Drugs Launches

India M&As Overtook PE Activity In 2022, Deal Momentum To Continue In 2023

India had a busy deals calendar in 2022, with companies led by Biocon striking large M&A deals while PE activity declined. Scrip pieced together data for infographics on these deals. A multitude of factors is expected to keep the momentum going in 2023

Commercial Scrip Perspectives

Ibrance Generics Arrive In India, Patient Programs Add Free Drug Component

Pfizer’s Ibrance is set to lose exclusivity in the US only by 2027, but the Indian market is buzzing with activity as generics including from top-ranked drug maker Sun Pharma vie for a share of the pie. Competing CDK4/6 inhibitors are already available but can cut-price palbociclib versions alter market dynamics?

Commercial India
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
    • Generic Drugs
    • OTC, Consumer
    • Specialty Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Integrace
    • Integrace Private Limited
    • Ichnos Sciences
UsernamePublicRestriction

Register